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Summary
Severe sepsis remains a poorly understood systemic inflammatory condition with high mortality
rates and limited therapeutic options in addition to organ support measures. Here we show that the
clinically approved group of anthracyclines acts therapeutically at a low dose regimen to confer
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robust protection against severe sepsis in mice. This salutary effect is strictly dependent on the
activation of DNA damage response and autophagy pathways in the lung, as demonstrated by
deletion of the ataxia telangiectasia mutated (Atm) or the autophagy-related protein 7 (Atg7)
specifically in this organ. The protective effect of anthracyclines occurs irrespectively of pathogen
burden, conferring disease tolerance to severe sepsis. These findings demonstrate that DNA
damage responses, including the ATM and Fancony Anemia pathways, are important modulators
of immune responses and might be exploited to confer protection to inflammation-driven
conditions, including severe sepsis.
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INTRODUCTION
Sepsis is a life-threatening condition that arises as a systemic inflammatory response to an
infection (Bone et al., 1992; Levy et al., 2003). It includes a continuum of clinical severity
ranging from systemic inflammatory response syndrome (SIRS), sepsis, severe sepsis to
septic shock (Suffredini and Munford, 2011). It is the leading cause of death in intensive
care units and the third cause of overall hospital mortality (Angus and Wax, 2001; Ulloa and
Tracey, 2005). In spite of substantial improvement in diagnosis and support measures, the
global annual mortality rate is ~28% (Hotchkiss and Karl, 2003), ranging from less than
10% in SIRS to up to 70% in septic shock (Angus and Wax, 2001; Annane et al., 2003). The
pathophysiology of sepsis remains poorly understood. As a result, the basic elements of
treatment – early antibiotics, prompt control of the source of infection and organ support -
have not changed substantially in the last fifty years, and attempts to translate basic research
results into effective new interventions have been met with limited or no success (Suffredini
and Munford, 2011). In the same period, the incidence of sepsis and its economic burden has
increased by 1% each year (Martin et al., 2003; Ulloa and Tracey, 2005), indicating the
urgent need for novel therapeutic options.
Inflammation is a response to harmful stimuli that limits tissue damage and aims at restoring
homeostasis (Medzhitov, 2008). Pathogen-associated molecular patterns (PAMPs) on
microorganisms and damage-associated molecular patterns (DAMPs) originating from dying
cells are sensed by the host through germline-encoded pattern recognition receptors (PRRs)
that recognize conserved signature structures in non-self and self (Janeway and Medzhitov,
2002). These sensors are present in both professional (including neutrophils, macrophages
and dendritic cells) and non-professional immune cells and their activation initiates
intracellular signaling cascades leading to the transcriptional expression of inflammatory
mediators, such as cytokines and chemokines. Inflammation needs to be effectively
terminated after removal of the original trigger for repair of damaged tissue to occur. In the
susceptible host, overproduction of inflammatory mediators or an exaggerated response to
their presence can lead to septic shock, tissue destruction or permanent loss of function
(Takeuchi and Akira, 2010).
There are two evolutionarily conserved defense strategies against infection that can limit
host disease severity. One relies on reducing pathogen load, i.e. resistance to infection, while
the other provides host tissue damage control, limiting disease severity irrespectively of
pathogen load, i.e. tolerance to infection (Raberg et al., 2009; Schneider and Ayres, 2008).
As demonstrated originally for plants and thereafter in Drosophila, tolerance to infection
also operates in mammals, as revealed for Plasmodium (Raberg et al., 2007; Seixas et al.,
2009) and polymicrobial infections in severe sepsis (Larsen et al., 2010).
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Here we show in an experimental mouse model that anthracyclines confer strong protection
against sepsis by increasing disease tolerance to infection, that is, acting irrespectively of
pathogen burden. We further show that ATM (ataxia telangiectasia mutated) kinase and the
induction of autophagy are strictly required for the in vivo protection against sepsis. These
molecular pathways provide strong damage control in tissues, specifically in the lung.
RESULTS
Anthracyclines confer strong protection against severe sepsis
In an in vitro chemical screen using ~2320 compounds, we identified several lead candidates
capable of inhibiting inflammatory cytokine production in response to E. coli challenge by
the THP-1 macrophage line (Figure S1a and Supplemental Table S1). This inhibitory effect
was dissociated from cytotoxicity of the compounds tested on THP-1 cells (Figure S1b).
Among these, we found 3 representatives of the anthracycline family of chemotherapeutic
agents namely epirubicin, doxorubicin and daunorubicin, and validated their inhibitory
activity on cytokine production (Figure S1c).
We then used the cecal ligation and puncture (CLP) mouse model of experimental sepsis to
investigate the in vivo effects of epirubicin (Rittirsch et al., 2009). In CLP, sepsis results
from a polymicrobial infection of abdominal origin, leading to bacteremia and a systemic
inflammatory response (Rittirsch et al., 2009). We adjusted CLP severity to a high-grade
sepsis, where at least 80% of C57BL/6 mice succumbed within 48 h after the initial
procedure. Under these conditions, epirubicin administered i.p. at the time of CLP and again
24 h later in a total of 1.2μg/g of body weight reproducibly and significantly (p<0.001)
increased the survival of C57BL/6 mice subjected to CLP by nearly 80%, without the use of
antibiotics (Figure 1a). A similar protective effect was observed in epirubicin-treated
animals with the same dose and schedule but administered i.v. (Figure S1d). This appeared
to be a general property of the anthracycline family because other representative members of
this family of drugs identified in the initial chemical screen conferred a similar degree of
protection against CLP (Figure 1b). The protective effect of anthracyclines was not
dependent on the mouse strain as outbread NMRI mice were similarly protected by
epirubicin (Figure 1c). Epirubicin was equally effective against another clinically relevant
pathogen causing sepsis, K. pneumoniae administered intranasally (Figure 1d), arguing that
epirubicin can be effective in the treatment of sepsis of different origins in addition to
peritoneal sepsis. Mice previously subjected to CLP and treated with epirubicin were not
immunocompromised as they could clear a secondary intranasal viral infection similarly to
control mice (Figure 1e). Taken together, these results indicate that low doses of the
anthracycline family of chemotherapeutic agents confer strong protection against severe
sepsis, without causing host immunosuppression.
Epirubicin acts therapeutically to promote disease tolerance to severe sepsis
We found that in epirubicin-treated mice subjected to CLP the bacterial load in blood and
target organs of sepsis, e.g., lung, liver, kidney and spleen 24 h post-CLP did not differ from
that of untreated controls (Figure 2a). While at 48 h post-CLP we noticed a trend towards a
lower bacterial load in the target organs of epirubicin-treated animals, the differences were
not statistically significant, even if most untreated control animals die between 24 and 48 h
after the CLP procedure. These results raised the possibility that the protective effect of
epirubicin in vivo is related to disease tolerance without directly affecting the pathogen
burden(Medzhitov et al., 2012). This idea was supported by the observation that the serum
concentrations of several markers of tissue damage such as LDH (lung and general cellular
damage), CK (muscle), ALT (liver) and urea (kidney) were substantially reduced to almost
basal levels in epirubicin-treated mice, 24 h after CLP, compared to untreated mice (Figure
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2b). In addition, we observed a substantial reduction in the levels of inflammatory mediators
including TNF, IL-1β, IL-6 and HMGB1 compared to non-treated CLP mice (Figure 2c).
We have also observed improvement of histological lesions in the lung, liver and kidney
after CLP by treatment with epirubicin (Figure S2). To explore this further in the absence of
bacteria, we found that the drug protected C57BL/6 mice from lethal septic shock caused by
lipopolysaccharide (LPS, endotoxin) (Figure 2d).
Large spectrum antibiotics such as meropenem are very effective at lowering bacteremia and
are standard drugs used in sepsis (Russell, 2006). We tested the efficacy of meropenem in
CLP in comparison to epirubicin and found that while meropenem delayed the death rate of
CLP-subjected mice, it did not prevent mortality (Figure 2e), in spite of a strong impact on
bacterial burden (Figure 2f). This was in sharp contrast to the action of epirubicin, that did
not interfere with bacteremia (Figure 2f) but prevented CLP-induced mortality (Figure 2e),
again arguing for a role of epirubicin in conferring disease tolerance against severe sepsis
(Larsen et al., 2010; Medzhitov et al., 2012).
Both epirubicin and meropenem decreased the amounts of IL-1β, TNF and HMGB1 in the
serum of mice subjected to CLP (Figure 2g). This indicates that whereas decreased
circulating levels of inflammatory mediators may contribute to confer protection against
severe sepsis, inhibition of IL-1β, TNF and HMGB1 is not sufficient per se to explain the
protective effect of epirubicin, which is in accordance with what is observed for other
therapeutic approaches in the clinical setting (Hotchkiss and Karl, 2003). Taken together
these data suggest that epirubicin acts through an additional alternative mechanism to
cytokine inhibition to confer tolerance to sepsis.
Epirubicin protection against sepsis is mediated by ATM
Next, in order to explore the molecular mechanism behind the protective effects of
anthracyclines, we used our in vitro assay system to perform a short hairpin RNA (shRNA)-
based screen in THP-1 cells, focusing on kinases and phosphatases and using IL-1β and
TNF secretion as assay readouts. While our in vivo results suggested the possibility that
anthracyclines ameliorate the lethal effects of sepsis by a mechanism affecting tissue
tolerance, we reasoned that our in vitro assay would be useful for the identification of
candidate pathways mediating the anthracycline effects. We found several negative
regulators of IL-1β productionin response to E. coli challenge, including the genes encoding
Ataxia Telangiectasia Mutated (ATM), Checkpoint Kinase 1 (CHEK1) and Ataxia
Telangiectasia and Rad3 Related (ATR) (Figure S3 and Supplemental Table S2). These
findings suggest that DNA damage response (DDR) components are negative regulators of
IL-1β secretion. Using a phospho-specific antibody against the activated form of ATM, we
found that although E. coli alone was a poor, but reproducible ATM activator (Figure S3),
epirubicin alone or in combination with E. coli triggered a robust ATM activation (Figure
S3). This was confirmed using immunoblotting (Figure S3).
ATM is a master regulator of the DDR (Ciccia and Elledge, 2010) and is known to be
activated by anthracyclines and other DNA damaging agents (Siu et al., 2004). Therefore we
used ATM-deficient mice to test the contribution of the DDR to the protective effect of
anthracyclines against severe sepsis. ATM-deficient (Atm−/−) mice were not protected by
epirubicin against CLP and died with similar kinetics to those of wild-type (Atm+/+) animals
that were treated with PBS alone (Figure 3a). We conclude that ATM expression is
necessary to mediate the protective effect of epirubicin in sepsis. In striking contrast to wild-
type mice (Figures 2b and c), in the absence of ATM, epirubicin no longer normalized the
serologic markers of organ lesion (Figure 3b) or decreased the levels of inflammatory
mediators (Figure 3c). However, in mice subjected to CLP and treated with etoposide (after
in vivo titration to find the best and most effective dose), an agent known to cause DNA
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double strand breaks and to activate ATM-dependent pathways (Montecucco and Biamonti,
2007), mortality induced by CLP was only partially rescued (Figure 3d), suggesting that
ATM is necessary but not sufficient for the protection conferred by anthracyclines against
sepsis.
In addition to double strand breaks (repaired in an ATM-dependent manner), anthracyclines
also cause DNA interstrand cross-links, a DNA lesion known to be repaired by the Fanconi
Anemia (FA) pathway (Ciccia and Elledge, 2010). Interestingly, FA patients were reported
to spontaneously overproduce TNF (Briot et al., 2008; Vanderwerf et al., 2009), possibly
because the FA protein FANCD2can directly inhibit TNF promoter activity (Matsushita et
al., 2011). In THP-1 cells, we observed that FANCD2 is activated in an ATM-independent
manner upon epirubicin treatment, as shown by its mono-ubiquitination (Figure 3e). These
findings support the independence of signaling events initiated by the generation of DNA
double strand breaks and DNA interstrand cross-links. We examined the contribution of this
pathway for epirubicin protection of CLP and found that Fancd2−/− mice were slightly but
significantly (p<0.05) impaired for the protective effects (Figure 3f).
These results suggest that activation of DDR is protective against sepsis. To further test this
hypothesis we have used whole body sub-lethal γ-irradiation. We found a significant
increase in the number of cells with γH2AX-positive foci (p<0.001), a surrogate marker of
ATM activation (Ciccia and Elledge, 2010), in the lungs of whole body sub-lethal γ-
irradiated mice as compared to controls (figure 3g). Mice subjected to CLP that were
irradiated showed a significant increased survival (p<0.001) as compared to non-irradiated
mice (Figure 3h). We conclude that the protective phenotype induced by epirubicin is
dependent on the activation of multiple pathways downstream of a DDR. The activation of
the ATM pathway is the main contributor, but the full protection requires the activation of
additional DDR pathways, including the FA pathway.
The protective effect of epirubicin is dependent on the autophagy pathway
Although it is possible that the dominant ATM-mediated protection against sepsis might rely
on ROS scavenging (Cosentino et al., 2010), on the induction of apoptosis of inflammatory
cells (Garrison et al., 2011), on the preservation of genomic stability (Westbrook and
Schiestl, 2010), or on the biogenesis of anti-inflammatory microRNAs such as miR-146a
(Zhang et al., 2011), we found no significant contribution for any of these processes (Figure
S4). We, therefore, explored a possible role for autophagy in this process, given that ATM is
a negative regulator of mTOR, which is itself, an inhibitor of autophagy (Alexander et al.,
2010a; Alexander et al., 2010b). Using autophagy-defective (Lc3b−/−) mice, we found that
the autophagy pathway is required for the in vivo effect of epirubicin (Figure 4a). Similarly
to Atm−/− mice (Figure 3b and c), epirubicin was not able to decrease the serologic markers
associated with organ lesion (Figure 4b) or to normalize cytokine levels in autophagy-
defective mice (Figure 4c).
We then used LC3b-GFP mice to study the contribution of the autophagy pathway in the
protection conferred by epirubicin. While FACS analysis shows that CLP alone induces
LC3b aggregation in different splenocyte populations, namely monocytes and neutrophils,
epirubicin treatment did not increase the autophagy pathway in these critical players in
sepsis (Figure 5a). We then tested the impact of epirubicin on the survival of a conditional
depletion of Atg7 specifically in neutrophils and monocytes upon CLP, using
Atg7loxP/loxPLysMCre GFP-LC3b animals. Strikingly, these animals were equally protected
by epirubicin as compared to control mice (Figure 5b), suggesting that the autophagy
pathway is not required in the myeloid compartment for the protective effects of epirubicin
against sepsis.
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Autophagy can be effectively monitored by the conversion and immobilization of LC3
(Kabeya et al., 2000). Because the autophagy pathway was not required in the myeloid
compartment for protection against sepsis by epirubicin, we then looked at target organs of
sepsis (lung, liver and kidney) using immunobloting to identify lipidation of LC3b as
indicative of activation of the autophagy pathway. We found that epirubicin specifically
induced lipidation of LC3b in the lung at 6 h, but not in the liver or kidney (Figure 5c).
Although LC3 was transiently lipidated after CLP in the liver at 6 and 24 h as previously
reported (Chien et al., 2011), levels of LC3 were not altered by epirubicin treatment (Figure
5c). We have further confirmed that autophagy was induced in the lung as shown by the
increase of LC3b positive vesicles in lung sections at 6 h and 24 h comparing epirubicin
treated and non-treated mice (Figure 5d).
We then deleted Atg7 specifically in the lung (Figure S5), using an adenovirus-expressing
CRE (Adcre) to intranasally infect Atg7loxP/loxP mice (Komatsu et al., 2005). When subjected
to CLP, these mice were no longer protected from CLP by epirubicin treatment (Figure 5e).
In contrast to control mice, in Atg7loxP/loxPAd cre mice the treatment with epirubicin does
not improve the levels of circulating markers of organ lesion (Figure 5f). Accordingly, we
observed a significant protective effect in survival after overexpression of ATG7 in the lung
using adenovirus (Figure 5g).
By assessing the levels of γH2AX in the lungs of control or epirubicin-treated CLP-
subjected mice, we found a significant increase in the number of cells with γH2AX-positive
foci in lungs of epirubicin-treated mice (Figure 5h). To test whether ATM activation was
also required in the lung, we used AtmloxP/loxP mice and Adcre to delete ATM specifically in
the lung. Upon Adcre-mediated ATM deletion in the lung, mice were no longer protected
against sepsis by treatment with epirubicin (Figure 5i). We therefore conclude that the
protective effect of epirubicin in sepsis is, at least in part, dependent on the activation of
ATM and of autophagy in target organs, namely the lung. These conclusions are further
supported by intranasal delivery of epirubicin or etoposide to the lung (Figure 5j), because
the protective effects as measured by survival are similar to the i.p. administration of those
drugs (Figure 5j).
Epirubicin has a 24 h therapeutic window to protect against sepsis
Finally, we studied the therapeutic window of epirubicin in mice. When given alone,
epirubicin conferred strong protection at the time of the procedure or until 3 h after the
initiation of CLP (Figure 6a). When administered only 6 h after CLP, epirubicin quickly lost
its protective effect (Figure 6a). However, if given in combination with meropenem, even
when this antibiotic is only administered 12 h after CLP, low dose epirubicin conferred
complete protection until at least 24 h after the initial procedure (Figure 6b and 6c). These
results suggest that anthracyclines can be used not only to prevent sepsis, but also that they
can act therapeutically when their administration is combined with a large spectrum
antibiotic.
Discussion
Here we report that epirubicin, and more generally the group of anthracyclines, are very
effective at conferring protection against severe sepsis in mice, even when used up to 24 h
after the onset of infection. This therapeutic window is likely to be sufficient to make these
drugs good candidates as useful therapeutic options in the clinic to reduce the mortality of
sepsis in most patients that are either in the hospital or seek medical attention within the first
few hours of symptoms initiation.
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Although we began our investigation of the use of anthracyclines in sepsis by virtue of their
effects in inhibiting inflammatory cytokine expression in myeloid cells in vitro, our studies
have identified a mode of protection that seems to be much stronger and perhaps completely
independent of such effects, and rather manifests at the level of DNA damage response and
autophagy-induced protection in the lung. Thus, our findings uncover an unexpected role for
these pathways in tissue (lung) tolerance to the pathological consequences of infection.
These findings are especially relevant given that agents discovered in studies over the last
few years targeting various pro-inflammatory cytokines have had limited success in humans.
Our studies suggest a critical role for protecting host tissues thereby conferring protection
against sepsis. Recent studies have highlighted the role of tissue tolerance to infection as an
important aspect of host pathology (Medzhitov et al., 2012).
Interestingly, the protective effect of epirubicin seems to act irrespectively of the host
pathogen burden, revealing that it confers disease tolerance to polymicrobial infection
(Larsen et al., 2010; Raberg et al., 2009; Schneider and Ayres, 2008). This finding reveals
that pharmacologic agents that provide tissue damage control can limit disease severity
irrespectively of pathogen load and represent a promising therapeutic strategy against sepsis.
Moreover, based on our identification of ATM as a major mediator of epirubicin effects, we
propose that this protein and other components of the DNA damage response machinery
constitute novel regulators of tolerance, without affecting pathogen resistance mechanisms.
Recent reports make our findings counter-intuitive as doxorubicin and daunorubicin have
been shown to induce acute inflammation when injected in the abdomen where they induce
cytokine secretion (Krysko et al., 2011; Sauter et al., 2011). However, the concentrations of
anthracyclines utilized in these studies were more than 10-fold higher than those used here.
By using lower concentrations we may reduce the cytotoxicity of these drugs and the
resulting release of pro-inflammatory DAMPs by dying cells and reveal the additional
pharmacological effects mediated by the surviving target cells. Interestingly,
fluoroquinolones that are bacterial type II topoisomerase inhibitors, as opposed to
anthracyclines, which are eukaryotic type II topoisomerase inhibitors, were reported to have
immunomodulatory effects (Dalhoff and Shalit, 2003) when used in supra-therapeutic
concentrations. Fluoroquinolones have been shown to protect against LPS model of septic
shock (Khan et al., 2000). While the molecular mechanisms that explain these effects have
not been elucidated, it has been proposed that higher doses of fluoroquinolones can inhibit
mammalian topoisomerase type II enzymes in addition to their bacterial targets (Dalhoff and
Shalit, 2003), an effect that can be achieved with very low doses of anthracyclines.
The induction of autophagy is a common response to many forms of cellular stress,
including DNA damage (Mizushima and Komatsu, 2011). The rationale for testing the role
of autophagy was based on the knowledge that ATM is a negative regulator of mTOR and
that mTOR is a negative regulator of autophagy(Alexander et al., 2010a; Alexander et al.,
2010b). We therefore reasoned that if epirubicin activates ATM (as we have confirmed),
then it is possible that it induces autophagy. This line of investigation made sense because
several reports(Chien et al., 2011; Nakahira et al., 2010) have suggested a protective role for
autophagy in sepsis. To probe the contribution of autophagy for the protective phenotype
conferred by epirubicin, we have used two different genetic deletions in the autophagy
pathway (LC3b and ATG7) and in both cases the protection normally conferred by
epirubicin is lost. This is considered one of the best and most compelling ways to test the
contribution of autophagy and the direction of autophagic flow (Klionsky et al., 2012).
Chien et al. have previously found that autophagy is transiently induced in the rat liver after
CLP (Chien et al., 2011), and later made similar observations in the rat kidney (Hsiao et al.,
2012). Chien et al. have speculated that the transient induction of autophagy in these organs
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could be required for protection and its decline at a later stage could contribute to the
functional failure in liver during polymicrobial sepsis. After we found autophagy induction
by epirubicin, we thought that one reason to explain anthracycline protection against CLP
could be the sustained activation of autophagy in the liver and/or kidney preventing its
decline as observed by Chien et al. Instead we found that both in the liver and in the kidney,
treatment with epirubicin did not change this pattern, but instead transiently induced
autophagy in the lung, a response that was not present in mice subjected to CLP in the
absence of epirubicin treatment. We also report that epirubicin is highly protective when
delivered directly to the lung and that overexpression of ATG7 specifically in the lung
improves survival to CLP. Together, these observations strongly suggest that lung protection
is critical and likely dominant because it prevents failure of additional organs, which makes
our findings all the more relevant as the lung is the organ that often shows the first signs of
dysfunction in septic patients and drives the failure of other target organs particularly the
kidney and later the liver (Hotchkiss and Karl, 2003).
Nakahira et al. demonstrate that depletion of the autophagic proteins LC3b and beclin 1
enhanced the activation of caspase-1 and secretion of IL-1β and IL-18 (Nakahira et al.,
2010). While we also observe inhibition of IL-1β secretion in vitro and in vivo by treatment
with epirubicin, this finding is not dependent on the decreased activation of caspase-1
mediated by autophagy because even low concentrations of epirubicin lead to higher levels
of active caspase-1 (Chora et al., data not shown) but this event is overshadowed by a strong
inhibition of IL-1β, as well as most of pro-inflammatory mediators that are NF-kB
dependent, at the transcriptional level. We have now identified the mechanism: epirubicin
targets the N-terminal region of p65, inhibiting transcription by blocking the DNA-binding
ability of NF-kB (Chora et al., data not shown). The Nakahira et al. report also suggested to
us that severe sepsis could cause DNA lesions capable of activating the inflammasome
leading to chronic inflammation and that the induction of autophagy could block the
inflammasome and prevent excessive inflammation. To address this possibility, we have
used comet assays to look at different types of DNA damage in response to bacterial
challenge in the presence and absence of epirubicin. We did find that E. coli alone triggers a
small but measurable increase of DNA single strand breaks (Neves-Costa et al.,
unpublished). However the presence of epirubicin does not decrease, rather it increases
DNA damage as compared to E. coli alone. Therefore, epirubicin does not decrease the
generation of DNA damaged species that can activate the inflammasome. We conclude that
while the Nakahira et al. work clearly shows that autophagic proteins regulate NALP3-
dependent inflammation by preserving mitochondrial integrity, the autophagy protection
conferred by epirubicin to CLP does not depend on the mechanisms demonstrated in the
Nakahira et al. paper, specifically the negative regulation of IL-1β secretion by autophagy.
Interestingly, the protective phenotype of epirubicin is strikingly similar to that of RIPK3-
deficient mice (Duprez et al., 2011), suggesting that epirubicin-mediated, ATM-dependent,
autophagy induction can possibly prevent TNF-driven necroptosis in such key organs in
sepsis pathology as the lung. In fact, there have been recent works that support the role of
autophagy in the inhibition of necroptosis (Bray et al., 2012; Degenhardt et al., 2006; Lu and
Walsh, 2012; Shen and Codogno, 2012), which could be achieved by targeting key
necroptosis signaling components (such as RIPK1 and RIPK3) for degradation. It is also
possible that autophagy protects against severe sepsis because its activation increases the
degradation of pro-inflammatory mediators with an important role in sepsis, like HMGB1
(Li et al., 2011). In addition, increased effective autophagy can be beneficial in sepsis due to
its critical role in the removal of damaged mitochondria in an ATM-dependent
manner(Valentin-Vega and Kastan, 2012). The molecular mechanisms at the basis of
epirubicin-induced protection in sepsis by autophagy are certainly an interesting topic for
future studies.
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Experimental Procedures
Animal Model and Anthracycline Treatment
Animal care and experimental procedures were conducted in accordance with Portuguese
and US guidelines and regulations after approval by the respective local committees
(Instituto de Medicina Molecular and Instituto Gulbenkian de Ciência). All mice used were
8–12 weeks old. Mice were bred and maintained under specific pathogen-free (SPF)
conditions. C57BL/6 and C57BL/6 Atm−/− mi ce were obtained from the Instituto
Gulbenkian de Ciência (a kind gift from Dr. Vasco Barreto). C57BL/6 Nrf2−/− mice were
provided originally from the RIKEN BioResource Center (Koyadai, Tsukuba, Ibaraki,
Japan) and subsequently by the Instituto Gulbenkian de Ciência. LC3b−/− (B6129PF2/J
background) and NMRI mice were purchased from Jackson and Charles River laboratories,
respectively. miR-146-deficient mice were generated in the Baltimore’s laboratory (Boldin
et al., 2011). Fancd2−/− mice were generated by the Grompe laboratory (Houghtaling et al.,
2003). Atg7loxP/loxP were generated by Masaaki Komatsu and obtained from the Green
laboratory. AtmloxP/loxP mice were generated and obtained from the F.W. Alt’s laboratory.
CLP was performed as described previously (Rittirsch et al., 2009). The endotoxemia model
was performed by injecting intraperitoneally (i.p.) a single dose of 50 μg/g body weight of
LPS (from E. coli serotype 026:B6; Sigma-Aldrich). Pulmonary monostrain infections were
carried out as described previously (Weber et al., 2011), using intranasal injection of
Klebsiella pneumoniae (ATCC13803) at 8x107 colony-forming units (CFU). Epirubicin
(Sigma-Aldrich), doxorubicin (Sigma-Aldrich), daunorubicin (Sigma-Aldrich) were
dissolved in PBS, etoposide (Sigma-Aldrich) was dissolved in DMSO, aliquoted and stored
at −80°C. Meropenem (AstraZeneca, Lisbon, Portugal). Epirubicin and daunorubicin (0.6μg/
g body weight), doxorubicin (0.5μg/g body weight), etoposide (2μg/g body weight) were
injected intraperitoneally at 0 and 24 h following CLP. Meropenem (20μg/g body weight
b.i.d.) was injected i.p. for 5 consecutive days.
Colony-Forming Units Assay
Blood samples from septic or mock CLP mice were collected by cardiac puncture at
indicated times after surgery. Mice were subsequentially perfused in toto with 10mL ice
cold PBS and spleen, liver and kidneys were surgically removed and homogenized in 5mL
of sterile PBS. Serial dilutions of blood and tissue homogenates were immediately plated on
Trypticase Soy Agar II plates supplemented with 5% Sheep Blood. CFUs were counted after
a 12 h incubation at 37 C.
Serology and Cytokine Measurement
Plasma from blood samples obtained 24 h post-CLP was collected after centrifugation.
LDH, CK, ALT and urea levels were measured using the BioAssay Systems kits (BioAssay
Systems, California) according to company’s protocol. Levels of TNF, IL-1β and IL-6 were
measured using the murine ELISA kits (R&D Systems, Minneapolis) according to
company’s protocol. Levels of HMGB1 were assessed using a murine ELISA kit (Shino
Test Corporation, Tokyo) according to company’s protocol.
Histology
Mice were euthanized, perfused in toto with 10mL ice cold PBS and lungs and livers were
surgically removed. Livers were placed in 10% phosphate buffered formalin for 24 h after
which were embedded in paraffin. Sections were subsequently incubated with a primary
antibody reactive to HMGB1 (Abcam, Cambridge, UK) followed by incubation with
biotinylated secondary antibody and then with biotinylated horseradish peroxidase. Staining
was developed by addition of diaminobenzidine (DAB) substrate (Vector Labs, Burlingame,
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CA) and counterstained with hematoxylin. Lungs were embedded in Tissue-Tek OCT
(Sakura, Alphen aan den Rijn, Netherlands), and snap-frozen in liquid nitrogen. Lung
sections (7 μm) were fixed in 1% paraformaldehyde in PBS for 2 min, followed by methanol
at −20°C for 10 min and then in acetone for 2 min. Detection of LC3b and histone γH2AX
was performed by incubating sections overnight at 4°C with rabbit polyclonal antibodies
specific for, respectively, LC3b (L7543, Sigma Aldrich, USA) and γH2AX (phosphoS139)
(ab2893; Abcam, Cambridge, UK); incubation with a secondary DyLight 488-coupled
antibody (Jackson ImmunoResearch Laboratories, West Grove, PA, USA) was for 1 h at
room temperature. Sections were counterstained with DAPI (0.5 μg/mL) to visualize DNA
and mounted in Vectashield (Vector Laboratories Inc., Burlingame, CA) before confocal
microscopy. Samples were examined with a Zeiss LSM 510 META laser scanning confocal
microscope (Carl Zeiss, Jena, Germany). The acquired images were analyzed using a
MATLAB (Mathworks; Natick, MA) routine developed in-house to perform automatic
threshold segmentation and enumeration of individual cell nuclei stained with DAPI.
In vivo Viral Infection and Viral Titer Assay
Murid herpesvirus-4 infection and viral particle quantification was performed as previously
described (Marques et al., 2008). Briefly, mice were intranasally inoculated with 1000 PFU
of MuHV-4 strain 68 in 20 μLof PBS under light isoflurane anaesthesia. At 6 and 12 days
post-infection, lungs were removed and homogenized in 5mLof Glasgow’s modified Eagle’s
medium (GMEM). Infectious virus titers in freeze-thawed lung homogenates were
determined by serial diluted suspension assay using Baby hamster kidney cells (BHK-21)
cultured in GMEM supplemented with 10% fetal bovine serum, 10% tryptose phosphate
broth, 2 mM glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin (GMEM). Plates
were incubated for four days, fixed with 10% formal saline and counterstained with
toluidine blue. Viral plaques were counted with a plate microscope. Cre-adenovirus were
obtained from the University of Iowa, prepared as a calcium-phosphate coprecipitate and
incubated for 20 min at room temperature. Atg7loxP/loxP and ATMloxP/loxP were subjected to
light isoflurane anesthesia and allowed to inhale 125μLof virus at a concentration of 2.5 ×
107PFU. Additionally, wild -type C57BL/6 mice were included as controls. Mice were
allowed to rest for 5 days after inhalation after which were subjected to CLP.
Stainings and Flow Cytometry
Peritoneal infiltrating leukocytes from either wild-type or LC3b-GFP transgenic animals
were obtained 24 h post CLP by lavage with 5 mL of sterile ice-cold PBS, washed and
blocked with mouse Ab anti-FcγIII/II (clone 93) receptor diluted in PBS containing 2% FCS
(v/v) for 20 min at 4°C. Surface markers were detected by incubating for 30 min at 4°C with
mouse Ab anti-CD4 (clone GK1.5), -CD8 (clone 53–6.7), -CD19 (clone 6D5), -Ly-6G
(clone 1A8) (all Biolegend) and -neutrophil monoclonal antibody (clone 7/4) (Abcam,
Cambridge, UK). Dead cells were excluded by co-staining with propidium iodide. Total cell
number was determined by flow cytometry using a fixed number of latex beads (Beckman
Coulter, CA, USA) co-acquired with a pre-established volume of the cellular suspension.
For phospho-ATM intracellular staining, stimulated THP-1 cells were washed and fixed
with ice-cold methanol. Mouse Ab anti-phosphoATM pS1981, clone 10H11.E12 (IgG1k)
(Rockland, MA, USA) was incubated for 60 min at room temperature followed by an
incubation of secondary Ab conjugated with Alexa 488 (Molecular Probes, CA, USA).
Fluorescence was measured by flow cytometry, and data analyzed using FlowJo software.
Immunoblotting
Mouse phospho-ATM (4526, Cell Signaling, Danvers, MA, 1:1000 dilution), rabbit total
ATM (2873, Cell Signaling, Danvers, MA, 1:1000 dilution), rabbit LC3b (Sigma, 1:1000
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dilution) and the rabbit Fancd2 (Novus Biologicals, CO, USA; 1:1000 dilution) Ab were
used overnight at 4°C. Primary Ab were detected using peroxidase conjugated secondary Ab
(1h; RT) and developed with SuperSignal chemiluminescent detection kit (Pierce,
Carcavelos, Portugal).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• Anthracyclines confer strong protection against severe sepsis.
• Anthracyclines act therapeutically by promoting disease tolerance to severe
sepsis.
• DDR and autophagy are required in the lung for anthracycline-induced
protection.
• ATM and FA pathways are required for protection.
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Figure 1. Epirubicin affords protection against severe sepsis
(a) Survival of C57BL/6 wild-type animals subjected to CLP treated with carrier (PBS) or
epirubicin (Epi) (0.6μg/g body weight) at the time of procedure and 24 hours later. (b)
Survival of C57BL/6 wild-type animals subjected to CLP treated with carrier (PBS),
epirubicin (Epi), doxorubicin (Doxo) or daunorubicin (Dauno). Treatment schedule and
doses as in (a). (c) Survival of NMRI mice subjected to CLP and treated with carrier (PBS)
or epirubicin (Epi) as in (a). (d) Survival of C57BL/6 wild-type animals following intranasal
inoculation of Klebsiella pneumoniae and treated with carrier (PBS) or epirubicin (Epi) as in
(a). (e) Quantification of infectious viral MuHV-4 particles in lung of C57BL/6 wild-type
animals previously subjected to mock CLP (S), mock CLP treated with epirubicin (S+E) or
CLP treated with epirubicin (C+E). Epirubicin treatment dose and schedule as in (a). Mice
were intranasally inoculated with 1000 PFU of MuHV-4 on day 3 post CLP and viral
particles quantified by plaque assay at days 6 and 12 post viral infection. Each circle
represents individual animals and horizontal lines indicate arithmetic means ± SEM from
two independent assays. The dashed horizontal line represents the limit of detection of the
assay. ns, not significant; *P<0.05; **P<0.01; ***P<0.001 (log-rank (Mantel-Cox) test for
(a) to (d) and Mann-Whitney test for (e)). See also Figure S1 and Table S1.
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Figure 2. Epirubicin promotes disease tolerance to severe sepsis
(a) Polymicrobial load (CFUs) in blood, lung, liver, kidney and spleen, at indicated time
points, of C57BL/6 animals undergoing CLP and treated with PBS (C+P) or epirubicin (C
+E) (0.6μg/g body weight) at the time of procedure and 24 hours later. Each circle
represents individual animals. Horizontal lines indicate arithmetic means ± SEM. (b) and
(c) Epirubicin counteracts tissue damage and inflammation associated with CLP as assessed
by (b) LDH, CK, ALT, urea and (c) TNF, IL-1β, IL-6 and HMGB1 plasma concentrations in
C57BL/6 wild-type animals 24 hours after mock CLP (S) (n=2) or CLP followed by
treatment with PBS (C+P) (n=5) or epirubicin (C+E) (n=7) as in (a). Results shown
represent arithmetic means ± SEM from duplicate (b) or triplicate (c) readings per animal.
(d) Survival of C57BL/6 wild-type animals following lethal LPS injection and treatment
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with carrier (PBS) or epirubicin (Epi) as in (a). (e) Survival of C57BL/6 wild-type animals
subjected to CLP treated with carrier (PBS), meropenem (40μg/g body weight/day) or
epirubicin (Epi) as in (a). (f) CFUs in blood, at indicated time, of C57BL/6 animals
undergoing mock CLP (S) or CLP followed by treatement with PBS (C+P), epirubicin (C
+E) or meropenem (C+M) as in (a). Each circle represents individual animals. Horizontal
lines indicate arithmetic means ± SEM. (g) IL-1β, TNF and HMGB1 plasma concentrations
in C57BL/6 wild-type animals 24 hours after CLP followed by treatment with PBS (C+P)
(n=4), epirubicin (C+E) (n=5) or meropenem (C+M) (n=5) as in (c). ns, not significant;
*P<0.05; **P<0.01; ***P<0.001 (log-rank (Mantel-Cox) test for (d) and (e), Mann-Whitney
test for (a) and (f), and unpaired t test for (b), (c) and (g)). See also Figure S2.
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Figure 3. The protection afforded by epirubicin against severe sepsis is mediated by ATM
(a) Survival of Atm+/+ and Atm−/− C57BL/6 animals subjected to CLP and treated with PBS
or epirubicin (Epi) with same schedule and dose as in fig 1. (b) LDH, CK, ALT, urea and (c)
TNF, IL-1β and IL-6 plasma concentrations in Atm−/− C57BL/6 animals 24 hours after mock
CLP (S) (n=2) or CLP followed by treatment with PBS (C+P) (n=8) or epirubicin (C+E)
(n=8) as in (a). Results shown represent arithmetic means ± SEM from triplicate readings
per animal. (d) Survival of PBS-, etoposide (Eto)-, and epirubicin (Epi)-treated wild-type
C57BL/6 animals undergoing CLP. Etoposide dose was 2μg/g body weight. Treatment
schedule as in (a). (e) FANCD2 and Ub-FANCD2 protein levels by immunoblotting in
THP-1 cells following E. coli challenge after a pre-incubation (1 hour) with carrier,
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epirubicin or KU-55933 as indicated. (f) Survival of Fancd2+/+ and Fancd2−/− animals
subjected to CLP and treated with PBS or epirubicin (Epi) with same schedule and dose as
in (a). (g) Representative sections of γH2AX staining and percentage of γH2AX+ cells per
field (right panel) in lungs isolated 1 hour after mice were subjected to whole body γ
irradiation (4 Gy). Results shown represent arithmetic means ± SD from 3 fields. (h)
Survival of C57BL/6 wild-type animals subjected to CLP following whole body γ
irradiation (4Gy) or treated with carrier (PBS) or epirubicin (Epi) as in (a). ns, not
significant; *P<0.05; **P<0.01; ***P<0.001 (log-rank (Mantel-Cox) test for (a), (d), (f) and
(h) and unpaired t test for (b), (c) and (g)). See also Figure S3 and Table S2.
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Figure 4. The ATM-dependent protection of epirubicin against severe sepsis relies on the
induction of autophagy
(a) Survival of Lc3b+/+ and Lc3b−/− animals subjected to CLP and treated with PBS or
epirubicin (Epi) with same schedule and dose as in fig 1. (b) LDH, CK, ALT, urea and (c)
TNF, IL-1β and IL-6 plasma concentrations in Lc3b−/− animals 24 hours after mock CLP (S)
(n=2) or CLP followed by treatment with PBS (C+P) (n=4) or epirubicin (C+E) (n=7) as in
(2b). Results shown represent arithmetic means ± SEM from triplicate readings per animal.
ns, not significant; *P<0.05; **P<0.01; ***P<0.001 (log-rank (Mantel-Cox) test for (a),
unpaired t test for (b) and (c)). See also Figure S4.
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Figure 5. The protective effect of epirubicin is dependent on the activation of ATM and the
autophagy pathway in the lung
(a) GFP expression in blood monocytes and neutrophils, isolated from transgenic LC3b-
GFP animals, 24 hours after mice were subjected to mock CLP (S) or CLP followed by
treatment with PBS (C+P) or epirubicin (C+E) (0.6μg/g body weight) at the time of
procedure and 24 hours later. Each circle represents individual animals. Horizontal lines
indicate arithmetic means ± SEM. (b) Survival of Atg7loxP/loxP and Atg7loxP/loxP LysMcre/cre
mice subjected to CLP and treated with PBS or epirubicin (Epi) with same schedule and
dose as in (a). (c) LC3B-I and LC3B-II protein levels by immunoblotting using a specific
antibody against LC3B in lung, liver and kidney, isolated at the indicated times, of naïve
C57BL/6 animals (C) or mice subjected to mock CLP (S) or CLP followed by treatment
with PBS (C+P) or epirubicin (C+E) as in (a). (d) Representative sections of LC3b staining
in lungs, isolated at the indicated times, of mice subjected to CLP followed by treatment
with PBS (C+P) or epirubicin (C+E) as in (a). (e) Survival of wild-type (B6) and
Atg7loxP/loxP animals subjected to CLP and treated with PBS or epirubicin (Epi) with same
schedule and dose as in (b) 5 days after inhalation of adenoviral vector encoding Cre
(AdCre). (f) LDH, CK, ALT and urea plasma concentrations in wild-type (B6 AdCre) and
Atg7loxP/loxP AdCre animals 24 hours after mock CLP (S) (n=2 for B6 AdCre) or CLP
followed by treatment with PBS (C+P) (n=5 for B6 AdCre and n=2 for Atg7loxP/loxP AdCre)
or epirubicin (C+E) (n=6 for B6 AdCre and n=3 for Atg7loxP/loxP AdCre) as in (a). (g)
Survival of wild-type (B6) animals subjected to CLP 4 days after inhalation of adenoviral
vector encoding GFP (AdGFP) or Atg7 (AdATG7). (h) Representative sections of γH2AX
staining and percentage of γH2AX+ cells per field (right panel) in lungs, isolated 6 hours
after mice were subjected to CLP followed by treatment with PBS (C+P) or epirubicin (C
+E) as in (a). Results shown represent arithmetic means ± SD from 10 fields. (i) Survival of
wild-type (B6) and AtmloxP/loxP animals subjected to CLP and treated with PBS or
epirubicin (Epi) with same schedule and dose as in (b) 5 days after inhalation of AdCre. (j)
Survival of C57BL/6 wild-type animals subjected to CLP treated with carrier (PBS),
etoposide (40μg/g body weight/day) or epirubicin (Epi) (0.6μg/g body weight) intranasally,
at the time of procedure and 24 hours later. ns, not significant; *P<0.05; **P<0.01;
***P<0.001 (log-rank (Mantel-Cox) test for (b), (e), (g), (i) and (j), Mann-Whitney test for
(a), and unpaired t-test for (f) and (h) (right panel)). See also Figure S5.
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Figure 6. Epirubicin confers protection against severe sepsis in a therapeutic manner
(a) Survival of C57BL/6 wild-type animals subjected to CLP treated with PBS or epirubicin
(same dose as in Figure 1) at indicated times in the absence of meropenem; (b) with
administration of meropenem (40μg/g body weight/day) starting at the time of the procedure
or (c) with meropenem treatment starting 12 hours after CLP. ns, not significant; *P<0.05;
**P<0.01; ***P<0.001 (log-rank (Mantel-Cox)).
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